SS Innovations International Inc. (NASDAQ: SSII) reported record first-quarter 2026 financial results, with revenue surging 116.8% year-over-year to $11.1 million, driven by accelerating commercial adoption of its SSi Mantra surgical robotic system. The company’s gross profit rose to $5.3 million from $1.1 million in the same period last year, reflecting higher system installations and increased procedure volumes.
The installed base of SSi Mantra systems reached 194 across 11 countries, with nearly 9,750 cumulative robotic procedures completed as of the end of the quarter. As of June 22, 2026, the cumulative number of multi-specialty procedures grew to 11,719, including 612 cardiac procedures, 175 telesurgeries, and 212 pediatric surgeries. Additionally, approximately 2,100 physicians have been trained on the SSi Mantra, which has been utilized to perform over 170 different types of procedures.
During the quarter, the company received regulatory approvals in Sri Lanka, Kenya, Indonesia, and the Philippines, expanding its international market access. SS Innovations also completed the world’s longest-distance robotic cardiac telesurgery, demonstrating the capabilities of its remote surgery platform. The company continues to pursue regulatory clearance in both the United States and Europe while strengthening its presence in emerging healthcare markets.
For more information, visit the company’s website at www.SSInnovations.com.
InvestorWire, a specialized communications platform, provided press release syndication for this announcement. For more details about InvestorWire, visit https://www.InvestorWire.com. See full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
